检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:董军 胡春花 白琳[1] 张柔 田臻 吴宇超[1,3] 朱丽[1] 任丹凤 刘锦锋[1] 杨瑗[1] 陈天艳[1] 赵英仁[1] 何英利[1] DONG Jun;HU Chun-hua;BAI Lin;ZHANG Rou;TIAN Zhen;WU Yu-chao;ZHU Li;REN Dan-feng;LIU Jin-feng;YANG Yuan;CHEN Tian-yan;ZHAO Ying-ren;HE Ying-li(Department of Infectious Disease,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061;Hospital of Zhen'an County,Shangluo 711500;Xi'an Jiaotong University Health Science Center,Xi'an 710061,China)
机构地区:[1]西安交通大学第一附属医院感染科,陕西西安710061 [2]镇安县医院,陕西商洛711500 [3]西安交通大学医学部,陕西西安710061
出 处:《西安交通大学学报(医学版)》2019年第3期406-410,431,共6页Journal of Xi’an Jiaotong University(Medical Sciences)
基 金:国家自然科学基金资助项目(No.8157041294; 8177031729);国家科技重大专项项目(No.2018ZX10301406)~~
摘 要:目的评估索磷布韦为基础的治疗方案在终末期肾病行血液透析治疗合并急性丙型肝炎患者群体中应用的安全性和有效性。方法纳入33位研究对象持续接受半量索磷布韦(200 mg)联合全量达卡他韦(90 mg)治疗24周,于治疗第0、4、8、12、16、20、24、28、32和36周分别检测血清HCV RNA、ALT、TBil水平,并评估药物相关不良反应。结果所有患者均在治疗结束后12周达到了持续病毒学反应(sustained virologic responses, SVRs),并且无药物相关的严重不良事件出现。结论半量索磷布韦(200 mg)联合全量达卡他韦(90 mg)的治疗对于终末期肾脏疾病行血液透析合并急性丙型肝炎的患者有效且安全。Objective To evaluate the safety and efficacy of sofosbuvir-based therapy in end-stage renal disease patients undergoing hemodialysis complicated with acute hepatitis C. Methods Totally 33 subjects who met the inclusion criteria received a half dose of sofosbuvir (200 mg) and a full dose of daclatasvir (90 mg) daily for 24 weeks.Then we detected the levels of HCV RNA,ALT,and TBil at 0,4,8,12,16,20,24,28,32 and 36 weeks respectively and evaluated the adverse drug reactions. Results All the patients made a sustained virological response at 12 weeks after the end of treatment,and there were no drug-related serious adverse events. Conclusion A half dose of sofosbuvir (200 mg once daily) plus a full dose of daclatasvir (90 mg once daily) was safe and effective for treatment of acute HCV infection in patients who were undergoing ESRD and were on hemodialysis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222